Clinical Trial Update: Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating a polysaccharide superparamagnetic iron oxide contrast agent for cardiovascular MRI in diabetic patients has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Cardiovascular Magnetic Resonance Imaging
• Diabetes

Drugs mentioned

• Polysaccharide superparamagnetic iron oxide contrast agent

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Diabetes, Magnetic Resonance Imaging | Phase 1, Phase 2 | Status: COMPLETED